Loading...
Please wait, while we are loading the content...
Similar Documents
Differentially expressed genes responsible for insensitivity of CD34+ cells to kinase inhibitors in patients with chronic myeloid leukemia
| Content Provider | Semantic Scholar |
|---|---|
| Author | Moreira-Nunes, Caroline Fa Azevedo, Tereza Cb Beltrão, Ana Cs Francês, Larissa Tvm Sousa, Rodrigo Gma Silva, Israel T. Da Silva, Artur Silva, Wilson Araújo Lemos, José Ar |
| Copyright Year | 2013 |
| Abstract | Background Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder characterized by formation of BCR-ABL fusion that encodes the p210 oncoprotein, which has a tyrosine kinase activity that confers an adaptive advantage to leukemic cells. Imatinib mesylate (IM) acts specifically on p210. Imatinib is able to reduce the differentiated cells (CD66b+) efficiently, but it has not the same effect on the stem cells (CD34+), which can be kept alive during treatment. Our aim was to identify expressed genes in CD34+ and CD66b+ cells as candidates for kinase inhibitors transport. |
| Starting Page | O1 |
| Ending Page | O1 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://bmcproc.biomedcentral.com/track/pdf/10.1186/1753-6561-7-S2-O1?site=bmcproc.biomedcentral.com |
| Alternate Webpage(s) | http://ftp.ncbi.nlm.nih.gov/pub/pmc/93/8b/1753-6561-7-S2-O1.PMC3624121.pdf |
| PubMed reference number | 3624121 |
| Volume Number | 7 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Binding corporate rules Chronic electrode implant Clone Fusion Proteins, bcr-abl Imatinib mesylate Leukemia, Myelocytic, Acute Mesylates Myeloid Leukemia Myeloid Leukemia, Chronic Myeloproliferative disease Oncogene Proteins OpenEdge Advanced Business Language (ABL) Patients Protein Tyrosine Kinase Stem cells |
| Content Type | Text |
| Resource Type | Article |